Market Research Logo

XOMA Corporation - Product Pipeline Review - 2016

XOMA Corporation - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘XOMA Corporation - Product Pipeline Review - 2016’, provides an overview of the XOMA Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by XOMA Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of XOMA Corporation
  • The report provides overview of XOMA Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses XOMA Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features XOMA Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate XOMA Corporation’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for XOMA Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding XOMA Corporation’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


XOMA Corporation Snapshot
XOMA Corporation Overview
Key Information
Key Facts
XOMA Corporation - Research and Development Overview
Key Therapeutic Areas
XOMA Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
XOMA Corporation - Pipeline Products Glance
XOMA Corporation - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
XOMA Corporation - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
XOMA Corporation - Drug Profiles
XOMA-213
Product Description
Mechanism of Action
R&D Progress
XOMA-358
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Undisclosed Disease
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing’s Disease
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Antagonize Parathyroid Hormone 1 Receptor for Hyperparathyroidism and Malignancy Induced Hypercalcemia
Product Description
Mechanism of Action
R&D Progress
XMet-A
Product Description
Mechanism of Action
R&D Progress
XOMA-129
Product Description
Mechanism of Action
R&D Progress
XOMA-3-BB
Product Description
Mechanism of Action
R&D Progress
Antibody to Modulate GPCR
Product Description
Mechanism of Action
R&D Progress
XOMA Corporation - Pipeline Analysis
XOMA Corporation - Pipeline Products by Target
XOMA Corporation - Pipeline Products by Route of Administration
XOMA Corporation - Pipeline Products by Molecule Type
XOMA Corporation - Pipeline Products by Mechanism of Action
XOMA Corporation - Recent Pipeline Updates
XOMA Corporation - Dormant Projects
XOMA Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
gevokizumab
XOMA Corporation - Company Statement
XOMA Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
XOMA Corporation, Key Information
XOMA Corporation, Key Facts
XOMA Corporation - Pipeline by Indication, 2016
XOMA Corporation - Pipeline by Stage of Development, 2016
XOMA Corporation - Monotherapy Products in Pipeline, 2016
XOMA Corporation - Out-Licensed Products in Pipeline, 2016
XOMA Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
XOMA Corporation - Phase II, 2016
XOMA Corporation - Phase I, 2016
XOMA Corporation - Preclinical, 2016
XOMA Corporation - Discovery, 2016
XOMA Corporation - Pipeline by Target, 2016
XOMA Corporation - Pipeline by Route of Administration, 2016
XOMA Corporation - Pipeline by Molecule Type, 2016
XOMA Corporation - Pipeline Products by Mechanism of Action, 2016
XOMA Corporation - Recent Pipeline Updates, 2016
XOMA Corporation - Dormant Developmental Projects,2016
XOMA Corporation - Discontinued Pipeline Products, 2016
XOMA Corporation, Subsidiaries
List of Figures
XOMA Corporation - Pipeline by Top 10 Indication, 2016
XOMA Corporation - Pipeline by Stage of Development, 2016
XOMA Corporation - Monotherapy Products in Pipeline, 2016
XOMA Corporation - Out-Licensed Products in Pipeline, 2016
XOMA Corporation - Pipeline by Target, 2016
XOMA Corporation - Pipeline by Route of Administration, 2016
XOMA Corporation - Pipeline by Molecule Type, 2016
XOMA Corporation - Pipeline Products by Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report